Related Experiment Videos
Erdosteine: its relevance in COPD treatment
1Università di Modena e Reggio Emilia, Clinica di Malattie dell'Apparato Respiratorio, Dipartimento di Oncologia, Ematologia e Patologie Apparato Respiratorio, Modena, Italy. moretti@unimo.it.
Expert Opinion on Drug Metabolism & Toxicology
|April 1, 2009
Summary
Erdosteine, an antioxidant mucolytic, benefits patients with chronic obstructive pulmonary disease (COPD). It improves symptoms, reduces exacerbations, and enhances quality of life in COPD management.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition characterized by irreversible airflow limitation.
- Oxidant/antioxidant imbalance plays a significant role in COPD pathogenesis.
Purpose of the Study:
- To evaluate the beneficial effects of erdosteine, a mucolytic agent with antioxidant properties, in managing COPD.
- To review existing research on erdosteine's efficacy in COPD and chronic bronchitis.
Main Methods:
- Systematic review of experimental and clinical trials.
- Analysis of erdosteine's pharmacological profile including mucolytic, antibacterial, antioxidant, and anti-inflammatory activities.
Main Results:
- Erdosteine administration (300 mg twice daily for 7-10 days) improved symptoms and reduced disease duration during acute exacerbations of chronic bronchitis/COPD.
- Long-term erdosteine treatment in stable COPD patients led to fewer exacerbations, reduced hospitalizations, and improved quality of life.
- Erdosteine appears most effective in COPD patients experiencing frequent, prolonged, or severe exacerbations.
Conclusions:
- Erdosteine demonstrates a multifactorial therapeutic action beneficial for COPD management.
- The drug offers significant advantages in both acute exacerbations and long-term control of COPD.
- Erdosteine is a promising agent for improving outcomes and quality of life in COPD patients, particularly those with severe exacerbation patterns.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...